Results 251 to 260 of about 1,982,916 (349)
Multimodal Imaging of Ductal Carcinoma In Situ: A Single-Center Study of 75 Cases. [PDF]
Urraro F +7 more
europepmc +1 more source
Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang +5 more
wiley +1 more source
Nanoluciferase-CD63 labeling reveals extracellular vesicle kinetics in a mouse intraductal model of ductal carcinoma in situ. [PDF]
Hladik C +7 more
europepmc +1 more source
Intelligent nano‐platforms in breast cancer therapy: Current advances and future perspectives
The smart nano platform in breast cancer treatment is designed with advanced nanocarriers, including liposomes, hydrogels, porous nanoparticles, and aptamer‐based systems. These systems are capable of targeted drug release and response to environmental stimuli.
Tina Rahimi, Moluk Aivazi
wiley +1 more source
Development and validation of a nomogram for differentiating granulomatous lobular mastitis from ductal carcinoma in situ. [PDF]
Li Y, Su L, Zhang Q, Liu Z.
europepmc +1 more source
RNA‐binding protein RBMS1: A new target for cancer diagnosis and treatment
This schematic illustrates the diverse regulatory roles of RNA‐binding motif single‐stranded interacting protein 1 (RBMS1) across multiple human cancers. In breast cancer, RBMS1 stabilizes B4GALT1 mRNA to promote PD‐L1 glycosylation, modulating tumor immune escape and immunotherapy efficacy.
Xingda Run +7 more
wiley +1 more source
Management of Low-Grade Ductal Carcinoma In Situ in a Supernumerary Breast: A Case Report. [PDF]
Bui A +4 more
europepmc +1 more source

